Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watchdog Group Blasts FDA’s Dwindling Oversight Of Non-Clinical Labs

This article was originally published in The Gray Sheet

Executive Summary

A nonprofit government watchdog group is criticizing FDA for scaling back inspections of laboratories that test medical devices early in the development process, before they are tested in humans

You may also be interested in...



510(k) Guidance Footnote May Signal Greater FDA Oversight Of Preclinical Testing

Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.

Funding Advice From FDA Science Board: Double Total Over Next Five Budgets

FDA Science Board members recommend a nearly $1.9 billion direct appropriation for the agency in fiscal 2009, a $375 million increase over 2008, and larger increases in each of the following five federal budgets

IGBA Urges WIPO To Revoke Patent Database Support

The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.

Topics

UsernamePublicRestriction

Register

MT027145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel